Coeptis Therapeutics, Inc. (COEP)

US — Healthcare Sector
Peers: LSB  SPRC  CVKD  HOTH  CDIO  ZVSA  ICU  DRMA 

Automate Your Wheel Strategy on COEP

With Tiblio's Option Bot, you can configure your own wheel strategy including COEP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol COEP
  • Rev/Share 0.6268
  • Book/Share 4.2677
  • PB 5.3411
  • Debt/Equity 0.2839
  • CurrentRatio 0.8229
  • ROIC -1.0141

 

  • MktCap 39565838.0
  • FreeCF/Share -2.3146
  • PFCF -5.5624
  • PE -3.5059
  • Debt/Assets 0.1367
  • DivYield 0
  • ROE -1.8281

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COEP and PPBI on Behalf of Shareholders
COEP, PPBI
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Read More
image for news SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COEP and PPBI on Behalf of Shareholders

About Coeptis Therapeutics, Inc. (COEP)

  • IPO Date 2020-12-17
  • Website https://coeptispharma.com
  • Industry Biotechnology
  • CEO David Mehalick
  • Employees 5
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.